Goldman Sachs analyst Neil Mehta raised the firm’s price target on Calumet (CLMT) to $24 from $20 and keeps a Buy rating on the shares ahead of the Q4 earnings report. Despite elevated leverage, the stock has potential catalysts from the operational ramp and regulatory clarity, alongside solid earnings contributions from its base business, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet Amends Credit Agreement, Extends Maturity to 2031
- Calumet price target raised to $19 from $18 at TD Cowen
- Calumet price target raised to $24 from $23 at BofA
- Elliott Backs Private Hypersonic Firm as U.S. Defense Spending Accelerates
- Calumet Specialty Products Completes Upsized Senior Notes Offering